Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All
It's possible that potential risk for thromboembolic events flagged in rheumatoid arthritis studies could be managed in labeling.
It's possible that potential risk for thromboembolic events flagged in rheumatoid arthritis studies could be managed in labeling.